Every condition I give I want defination aetiology type predisposing factors pathogenesis clinical feature with sign diagnosis or investigation and complications
Ankylising spondylitis
"ankylosing spondylitis"[MeSH Terms] AND diagnosis
| Group | Subtype |
|---|---|
| Axial SpA | Radiographic (AS) / Non-radiographic axial SpA |
| Peripheral SpA | Psoriatic arthritis, Reactive arthritis, Enteropathic arthritis |
| Factor | Detail |
|---|---|
| HLA-B27 positivity | Most critical genetic risk; ~90% of patients carry it |
| Sex | Male:female ratio is 3:1; males have more severe spinal disease |
| Age | Young adults, typically 2nd-3rd decade; onset rarely after 45 |
| Family history | Strong familial clustering; first-degree relatives have significantly elevated risk |
| Race/Ethnicity | HLA-B27 rare in Australian Aboriginals; prevalent in 50% of western Canadian native tribes |
| Gut dysbiosis | Subclinical ileocolitis and altered microbiome implicated |
| Recurrent genitourinary/enteric infections | May trigger disease in genetically susceptible individuals |
| Investigation | Finding |
|---|---|
| HLA-B27 | Positive in ~90% of cases |
| X-ray pelvis/SI joints | Sacroiliitis (bilateral, symmetrical); "bamboo spine" (late) |
| MRI SI joints | Gold standard for EARLY disease; shows bone marrow oedema (active inflammation) before X-ray changes |
| ESR / CRP | Elevated in active disease (not always raised) |
| FBC | Mild normocytic anaemia in active disease |
| Rheumatoid factor | Negative (seronegative) |
| ANA | Negative |
| X-ray spine | Syndesmophytes, "squaring" of vertebrae, "bamboo spine" (advanced) |
| BASMI | Bath AS Metrology Index - measures spinal mobility |
| BASDAI | Bath AS Disease Activity Index - patient-reported disease activity score |
| Schober's test | Objective lumbar spine mobility measurement |
| Slit-lamp eye exam | For anterior uveitis |
| Echo/ECG | If aortic regurgitation or AV block suspected |
| Complication | Detail |
|---|---|
| Bamboo spine | Complete spinal fusion; loss of all mobility |
| Spinal fracture | Even minor trauma can cause fracture through ankylosed spine (often at C5-C6); high risk of spinal cord injury |
| Cauda equina syndrome | Late rare complication due to dural ectasia and arachnoid adhesions |
| Osteoporosis | From local chronic inflammation and abnormal biomechanical loading; leads to compression fractures |
| Aortic regurgitation | Aortitis causes root dilatation; may need valve replacement |
| Heart block / AV conduction defects | From inflammation of the conduction system |
| Anterior uveitis | Recurrent; may lead to synechiae, glaucoma, cataract, vision loss |
| Restrictive lung disease | Chest wall rigidity from costovertebral fusion reduces thoracic excursion |
| Apical fibrobullous disease | Upper lobe bilateral fibrocystic change; may be colonised by Aspergillus |
| Amyloidosis | Secondary (AA) amyloidosis from chronic inflammation (rare, late) |
| Work disability | Significant impact on quality of life and functional capacity |
| Spondylodiscitis | Destructive discovertebral lesion (Andersson lesion) |
Snogrens syndrome
"Sjogren syndrome"[MeSH Terms] AND diagnosis
| Type | Description |
|---|---|
| Primary Sjögren's Syndrome | Sicca features alone; no other associated autoimmune disease |
| Secondary Sjögren's Syndrome | Occurs alongside RA, SLE, systemic sclerosis, polymyositis, or other CTD |
| Juvenile Sjögren's | Onset before age 16; rarer; classification criteria may be less sensitive |
| Factor | Detail |
|---|---|
| Sex | Females >90% of patients (F:M ~9:1) |
| Age | Most commonly presents in the 4th-5th decade |
| HLA type | HLA-B8, HLA-DR3 genotypes increase susceptibility |
| Family history | First-degree relatives have elevated risk; familial clustering seen |
| Other autoimmune disease | RA, SLE, systemic sclerosis predispose to secondary Sjögren's |
| Viral infections | Prior EBV, HCV, HTLV-1 infections implicated |
| Hormonal | Oestrogen deficiency (post-menopausal) may contribute |
| System | Features |
|---|---|
| Constitutional | Fatigue, low-grade fever, myalgia, arthralgia |
| Musculoskeletal | Non-erosive arthritis, myositis |
| Skin | Palpable and non-palpable purpura, urticarial vasculitis, Raynaud's phenomenon, erythema nodosum |
| Pulmonary | Interstitial lung disease (NSIP, UIP), lymphocytic interstitial pneumonia (LIP), bronchiectasis, small airways disease |
| Renal | Distal (type 1) renal tubular acidosis (~5-10%), tubulointerstitial nephritis, glomerulonephritis |
| Neurological | Peripheral sensorimotor neuropathy, small-fibre neuropathy, trigeminal neuropathy, dorsal root ganglionopathy, CNS demyelination (mimics MS) |
| Vascular | Cryoglobulinaemic vasculitis (palpable purpura + neuropathy + GN triad) |
| GI | Dysphagia (oesophageal dysmotility), gastroesophageal reflux, primary biliary cholangitis association |
| Thyroid | Autoimmune thyroiditis (Hashimoto's) associated |
| Haematological | Lymphadenopathy, splenomegaly, leukopenia, thrombocytopenia, anaemia |
| Item | Score |
|---|---|
| Lip (minor salivary gland) biopsy - focal lymphocytic sialadenitis with focus score ≥1 foci/4mm² | 3 |
| Anti-Ro/SS-A positive | 3 |
| Ocular staining score ≥5 in at least one eye | 1 |
| Schirmer's test ≤5 mm/5 min in at least one eye | 1 |
| Unstimulated whole saliva flow rate ≤0.1 mL/min | 1 |
| Investigation | Findings |
|---|---|
| Anti-Ro/SS-A antibodies | Present in ~70-75% (most sensitive) |
| Anti-La/SS-B antibodies | Present in ~40-50% (more specific); rarely positive without anti-Ro |
| ANA | Positive in >80% (speckled pattern) |
| Rheumatoid factor | Positive in ~50-75% |
| Serum immunoglobulins | Polyclonal hypergammaglobulinaemia |
| FBC | Leukopenia, lymphopenia, normocytic anaemia, thrombocytopenia |
| ESR / CRP | ESR elevated; CRP often normal (paradoxically) |
| Complement (C3, C4) | Low C4 - risk marker for lymphoma |
| Cryoglobulins | Type II/III - if vasculitis present |
| Schirmer's test | ≤5 mm wetting in 5 minutes = lacrimal hypofunction |
| Rose Bengal / lissamine green staining | Highlights devitalised corneal epithelium |
| Minor salivary gland biopsy (lip biopsy) | Focal lymphocytic sialadenitis - GOLD STANDARD histology; focus score ≥1/4mm² |
| Sialography | Sialectasis in 85-97% of patients |
| Salivary gland scintigraphy | Reduced uptake and excretion |
| Sialometry | Unstimulated whole salivary flow rate ≤0.1 mL/min |
| MRI/ultrasound salivary glands | Glandular heterogeneity, lymphoepithelial lesions |
| Renal function / urine pH | RTA type 1: hyperchloraemic normal anion gap acidosis, urine pH >5.5 |
| HRCT chest | ILD patterns (NSIP, UIP, LIP) |
| Complication | Detail |
|---|---|
| Non-Hodgkin's Lymphoma (NHL) | Most serious; prevalence 3-5%; risk nearly 20x the general population; marginal zone B-cell type most common; triggered by chronic B-cell stimulation. High-risk features: persistent parotid enlargement, lymphadenopathy, splenomegaly, low C4, cryoglobulinaemia, neutropenia |
| Dental caries | Severe, rapidly progressive; affects gingival margins due to loss of saliva's buffering and antibacterial properties |
| Oral candidiasis | Candida albicans overgrowth due to reduced salivary flow |
| Keratitis / Corneal ulceration | Chronic corneal desiccation leading to keratitis, corneal thinning, ulceration, scarring, and vision loss |
| Interstitial lung disease | NSIP and UIP patterns; can progress to respiratory failure |
| Renal tubular acidosis (Type 1) | Nephrolithiasis, nephrocalcinosis, hypokalaemia, osteomalacia |
| Peripheral neuropathy | Painful dysaesthesias; dorsal root ganglionopathy; mononeuritis multiplex |
| CNS demyelination | Mimics multiple sclerosis; optic neuropathy, transverse myelitis |
| Cryoglobulinaemic vasculitis | Triad of purpura + neuropathy + glomerulonephritis; serious systemic complication |
| Pulmonary hypertension | Rare but serious |
| Neonatal lupus / congenital heart block | Anti-Ro/SS-A antibodies cross the placenta; fetal congenital complete heart block is a risk in pregnant patients |
| Recurrent infections | Secondary to glandular dysfunction (eye, mouth, lung, vagina) |
| Gastroesophageal reflux | Reduced salivary buffering of gastric acid |
Osteomyelitis
"osteomyelitis"[MeSH Terms] AND treatment
| Route | Details |
|---|---|
| Haematogenous spread | Most common in children; bacteria seed the metaphysis during bacteraemia |
| Contiguous spread | From adjacent soft tissue infection, septic arthritis, infected wound, or pressure sore |
| Direct inoculation | Open (compound) fractures, orthopaedic surgery, penetrating trauma |
| Setting | Common Organisms |
|---|---|
| Most common (all ages) | Staphylococcus aureus (most frequent overall; binds bone collagen) |
| Neonates | Group B Streptococcus, E. coli |
| Children | S. aureus, Group A Streptococcus |
| Sickle cell disease | Salmonella spp. (most common), S. aureus, gram-negative enteric organisms |
| IV drug users | Pseudomonas aeruginosa, Serratia, S. aureus |
| Diabetic foot | Polymicrobial, S. aureus, gram-negatives, anaerobes |
| Post-surgical / open fractures | Mixed, including S. aureus, coagulase-negative Staphylococci, gram-negatives |
| Immunocompromised | Fungi (Aspergillus, Candida, Cryptococcus), atypical mycobacteria |
| Tuberculosis (Pott's disease) | Mycobacterium tuberculosis - 40% of TB osteomyelitis affects the spine |
| No organism identified | In ~50% of cases, cultures are negative |
| Type | Features |
|---|---|
| Acute osteomyelitis | Duration <2 weeks; predominantly neutrophilic inflammation; no bone necrosis/sequestrum yet |
| Subacute osteomyelitis | 2 weeks to 3 months; more indolent; Brodie's abscess (walled-off abscess in metaphysis) is a classic form |
| Chronic osteomyelitis | >3 months; hallmark is dead bone (sequestrum) surrounded by new bone (involucrum); draining sinuses may form |
| Stage | Description |
|---|---|
| Stage 1 - Medullary | Infection confined to medullary cavity (e.g., haematogenous) |
| Stage 2 - Superficial | Cortical surface infection from contiguous focus |
| Stage 3 - Localised | Full-thickness cortical involvement; structurally stable bone |
| Stage 4 - Diffuse | Through-and-through involvement; bone structurally unstable |
| Factor | Detail |
|---|---|
| Age | Children (haematogenous); elderly (contiguous/diabetic) |
| Diabetes mellitus | Particularly diabetic foot osteomyelitis |
| Sickle cell disease | Bone infarctions create susceptible foci; splenic dysfunction |
| IV drug use | Recurrent bacteraemias seeding unusual sites (vertebrae, sternoclavicular joint) |
| Immunocompromise | HIV, malignancy, immunosuppressive therapy, corticosteroids |
| Trauma / open fractures | Direct inoculation of bone |
| Orthopaedic implants / prostheses | Biofilm formation on metal surfaces |
| Peripheral vascular disease | Reduced blood supply to limbs; especially feet |
| Malnutrition / chronic disease | Impaired host defences |
| Microtrauma | Encourages bacterial seeding in metaphyseal vessels |
| Prior osteomyelitis | Risk of reactivation in chronic disease |
| TB exposure / immunosuppression | Mycobacterial osteomyelitis risk |
| Investigation | Findings |
|---|---|
| Blood cultures | Positive in ~50% of haematogenous cases - obtain before antibiotics |
| WBC / FBC | Leukocytosis (neutrophilia) in acute; may be normal in chronic |
| ESR | Elevated - useful for monitoring response to treatment |
| CRP | Elevated; more sensitive and rapidly normalises with treatment |
| Procalcitonin | Elevated; useful marker of bacterial infection |
| Plain X-ray | Normal in first 10-14 days; later shows periosteal reaction, lytic lesion, bony destruction, sequestrum/involucrum; "bone-within-a-bone" sign in chronic disease |
| MRI (Gold Standard) | Most sensitive and specific; shows bone marrow oedema, subperiosteal abscess, soft tissue involvement early - investigation of choice |
| Bone scintigraphy (Technetium-99m) | Shows increased uptake early (within 24-72 hrs); useful when MRI unavailable or contraindicated |
| CT scan | Better defines cortical destruction, sequestrum, cloaca, and soft tissue abscesses; guides biopsy |
| Ultrasound | Detects subperiosteal abscess and joint effusion; guides aspiration |
| Bone biopsy + culture | GOLD STANDARD for identifying causative organism; essential for targeted antibiotic therapy; culture from bone specimen preferred |
| Wound/sinus swab cultures | Unreliable (often surface contaminants); not recommended for diagnosis |
| Histopathology (bone biopsy) | Acute: neutrophilic infiltrate, bone necrosis. Chronic: lymphocytes, plasma cells, marrow fibrosis, sequestrum. TB: caseating granulomas |
| Tuberculin skin test / IGRA | If TB osteomyelitis suspected |
| HbA1c / blood glucose | Screen for diabetes |
| Sickle cell screen | In appropriate population |
| Complication | Detail |
|---|---|
| Chronic osteomyelitis | Occurs in 5-25% of acute cases; particularly with delayed diagnosis, inadequate treatment, bone necrosis, or poor host immunity; persistent sequestrum acts as nidus |
| Septic arthritis | Spread of infection into adjacent joint; risk of permanent joint destruction and articular cartilage loss |
| Growth disturbance | In children, infection of the physis (growth plate) causes premature fusion → leg length discrepancy, angular deformity |
| Pathological fracture | Bone weakened by infection and necrosis; especially in chronic osteomyelitis |
| Draining sinus tracts | Persistent sinuses connecting bone to skin surface; chronic discharge |
| Squamous cell carcinoma (Marjolin's ulcer) | Malignant transformation of chronically discharging sinus tract epithelium (rare but serious) |
| Sarcoma | Rare malignant transformation within chronically infected bone |
| Secondary (AA) amyloidosis | From chronic sustained inflammation; leads to renal failure |
| Bacteraemia / Sepsis | Systemic dissemination; endocarditis |
| Psoas abscess | In vertebral (TB) osteomyelitis; may track to groin |
| Spinal cord compression / paraplegia | In vertebral osteomyelitis; from abscess or vertebral collapse (Pott's paraplegia) |
| Avascular necrosis | Loss of blood supply leads to bone segment death |
| MRSA infection | Particularly with Panton-Valentine leukocidin (PVL)-producing strains; increases morbidity significantly |
| Recurrence | Chronic osteomyelitis may remain dormant for years and reactivate |
Cervical spondylosis Small easy flow chart pathogenesis with other thing told earlier
"cervical spondylosis"[MeSH Terms] AND management
| Cause | Detail |
|---|---|
| Age-related degeneration | Primary cause; disc water content decreases with age → disc collapse |
| Genetic factors | Family history; predisposition to early disc degeneration |
| Mechanical loading | Repetitive microtrauma, chronic stress on cervical spine |
| Occupation | Frequent lifting, driving, prolonged neck flexion |
| Cigarette smoking | Accelerates disc degeneration via reduced disc nutrition |
| Previous trauma | Accelerates degenerative cascade |
| Congenitally narrow spinal canal | Predisposes to myelopathy even with mild degeneration |
| Type | Description |
|---|---|
| 1. Discogenic neck pain (axial pain) | Pain from disc degeneration without neural compression |
| 2. Cervical radiculopathy | Nerve root compression → arm pain, paresthesias, weakness in dermatomal distribution |
| 3. Cervical myelopathy | Spinal cord compression → upper and lower motor neuron signs |
| 4. Myeloradiculopathy | Combined cord + root compression |
AGEING + MECHANICAL STRESS + GENETIC PREDISPOSITION
│
▼
┌─────────────────────────────────┐
│ Nucleus Pulposus Dehydration │
│ (loss of proteoglycans/water) │
└─────────────┬───────────────────┘
│
▼
┌─────────────────────────────────┐
│ Disc Height Loss │
│ + Annular Tears / Fissures │
└─────────────┬───────────────────┘
│
▼
┌─────────────────────────────────┐
│ Increased Load on │
│ - Facet joints │
│ - Uncovertebral joints (Luschka│
└─────────────┬───────────────────┘
│
▼
┌─────────────────────────────────┐
│ Reactive Osteophyte Formation │
│ (vertebral endplates, facets, │
│ uncovertebral joints) │
└─────────────┬───────────────────┘
│
▼
┌─────────────────────────────────┐
│ Loss of Cervical Lordosis │
│ + Ligamentum Flavum Hypertrophy│
└─────────────┬───────────────────┘
│
┌──────────┴──────────┐
▼ ▼
┌───────────────┐ ┌──────────────────────┐
│ Neural Foramen│ │ Central Spinal Canal │
│ Narrowing │ │ Narrowing │
└───────┬───────┘ └──────────┬───────────┘
│ │
▼ ▼
┌───────────────┐ ┌──────────────────────┐
│ RADICULOPATHY │ │ MYELOPATHY │
│ (nerve root │ │ (spinal cord │
│ compression) │ │ compression) │
└───────────────┘ └──────────────────────┘
| Root | Level | Pain | Weakness | Reflex Lost | Sensory Loss |
|---|---|---|---|---|---|
| C5 | C4-C5 | Shoulder, lateral arm | Deltoid, biceps | Biceps ↓ | Lateral arm |
| C6 | C5-C6 (most common) | Thumb, index finger | Biceps, wrist extensors | Brachioradialis ↓ | Thumb & index |
| C7 | C6-C7 | Middle finger | Triceps, wrist flexors | Triceps ↓ | Middle finger |
| C8 | C7-T1 | Ring & little finger | Finger flexors, intrinsics | Finger flexor ↓ | Ring & little finger |
| Investigation | Finding |
|---|---|
| Lateral cervical X-ray | Disc space narrowing, osteophytes ("lipping"), loss of lordosis, foraminal narrowing, canal diameter measurement (normal ≥14 mm; relative stenosis 10-13 mm; absolute stenosis <10 mm) |
| AP cervical X-ray | Uncovertebral osteophytes, foraminal narrowing |
| Flexion-extension X-rays | Assess segmental instability |
| MRI (Gold Standard) | T2 decreased disc signal ("dark disc"), disc-osteophyte complex, cord compression, cord signal change (myelomalacia = T2 hyperintensity = poor prognosis), root compression |
| CT scan | Better bony detail; calcified disc, osteophytes; CT myelography if MRI contraindicated |
| CT myelography | Delineates neural compression when MRI is contraindicated |
| EMG / Nerve Conduction Studies | Differentiates radiculopathy from peripheral neuropathy; identifies affected root level |
| Somatosensory Evoked Potentials (SSEPs) | Detects subclinical myelopathy; assesses posterior column function |
| Motor Evoked Potentials (MEPs) | Assesses corticospinal tract involvement |
| Pavlov (Torg) ratio | Canal width / vertebral body width on lateral X-ray; <0.8 = risk factor for myelopathy |
| Complication | Detail |
|---|---|
| Cervical myelopathy | Progressive spastic weakness; if untreated → quadriplegia |
| Irreversible cord damage (myelomalacia) | T2 signal change on MRI = gliosis/necrosis; permanent neurological deficit |
| Catastrophic cord injury | Minor trauma (e.g., fall) on an already compressed cord → acute quadriplegia |
| Chronic pain and disability | Significant impact on quality of life and work capacity |
| Adjacent segment disease | After surgical fusion, accelerated degeneration at adjacent levels |
| Vertebral artery compression | Osteophytes may compress the vertebral artery → vertebrobasilar insufficiency, dizziness, drop attacks |
| Dysphagia | Anterior osteophytes can compress the oesophagus (rare) |
| Bladder/bowel dysfunction | From myelopathy; urinary urgency/retention; faecal incontinence |
| Falls and fractures | Gait disturbance from myelopathy increases fall risk |
| Post-operative complications | ACDF: adjacent segment degeneration, graft failure, C5 palsy, dysphagia. Laminoplasty: axial neck pain, loss of motion |
Lumbar spondylosis
| Cause | Detail |
|---|---|
| Age-related degeneration | Primary cause; disc desiccation begins in the 2nd-3rd decade |
| Genetic predisposition | Strong familial component; early disc degeneration runs in families |
| Mechanical overload | Repetitive heavy lifting, axial loading, prolonged sitting |
| Obesity | Increased axial load on lumbar discs and facets |
| Occupational factors | Manual labour, truck driving, frequent bending/twisting |
| Smoking | Reduces disc nutrition via vascular effects |
| Previous lumbar trauma | Accelerates degenerative cascade |
| Congenitally narrow canal | Predisposes to early stenosis symptoms |
| Systemic disease | Paget's disease, ankylosing spondylitis, acromegaly, fluorosis can cause secondary stenosis |
| Type | Description |
|---|---|
| 1. Discogenic back pain | Axial low back pain from disc degeneration; no neural compression |
| 2. Lumbar disc herniation | Nucleus pulposus herniation compressing a nerve root (sciatica) |
| 3. Lumbar radiculopathy | Nerve root compression from disc, osteophyte, or foraminal stenosis |
| 4. Lumbar spinal stenosis | Narrowing of spinal canal / lateral recess / foramen compressing neural elements |
| 5. Spondylolisthesis | Vertebral slip due to facet incompetence / pars defect |
| 6. Cauda equina syndrome | Severe central compression of sacral nerve roots - surgical emergency |
AGEING + GENETIC FACTORS + MECHANICAL OVERLOAD
│
▼
┌──────────────────────────────────┐
│ Nucleus Pulposus Desiccation │
│ (loss of water, proteoglycans) │
└──────────────┬───────────────────┘
│
▼
┌──────────────────────────────────┐
│ Disc Height Loss │
│ + Annular Tears / Fissures │
│ + Endplate Changes (Modic) │
└──────────────┬───────────────────┘
│
▼
┌──────────────────────────────────┐
│ Increased Load Transferred to: │
│ - Posterior facet joints │
│ - Posterior longitudinal lig. │
└──────────────┬───────────────────┘
│
▼
┌──────────────────────────────────┐
│ Facet Osteoarthritis │
│ + Vertebral Endplate Osteophytes│
│ + Disc Bulge / Annular Retropul │
└──────────────┬───────────────────┘
│
▼
┌──────────────────────────────────┐
│ Ligamentum Flavum Hypertrophy │
│ + Facet Capsule Hypertrophy │
│ (40% of canal compression from │
│ soft tissues alone) │
└──────────────┬───────────────────┘
│
┌──────────┼──────────────┐
▼ ▼ ▼
┌──────────┐ ┌──────────┐ ┌────────────┐
│ Discogen-│ │ Foraminal│ │ Central │
│ ic Pain │ │ Narrowing│ │ Stenosis │
└──────────┘ └────┬─────┘ └─────┬──────┘
│ │
▼ ▼
┌──────────┐ ┌───────────────┐
│RADICULOP-│ │ NEUROGENIC │
│ATHY │ │ CLAUDICATION │
│(sciatica)│ │ / Cauda equina│
└──────────┘ └───────────────┘
NOTE: On EXTENSION → ligamentum flavum buckles
inward + disc bulges anteriorly = WORST compression.
On FLEXION → canal opens = RELIEF (e.g., leaning
forward on shopping cart = "shopping cart sign").
| Root | Level | Pain (Dermatome) | Weakness | Reflex Lost | Sensory Loss |
|---|---|---|---|---|---|
| L3 | L2-L3 | Anterior thigh, medial knee | Quadriceps | Knee jerk ↓ | Medial thigh |
| L4 | L3-L4 | Medial lower leg | Tibialis anterior | Knee jerk ↓ | Medial lower leg |
| L5 | L4-L5 (most common) | Lateral leg → dorsum of foot | EHL (great toe extension) | No reliable reflex | Dorsum of foot, 1st webspace |
| S1 | L5-S1 | Posterior leg → heel/sole | Gastrocnemius, peronei | Ankle jerk ↓ | Lateral foot, heel |
| Feature | Neurogenic Claudication | Vascular Claudication |
|---|---|---|
| Pain location | Buttocks, thighs, calves | Calf primarily |
| Relief | Sitting / flexion | Stopping walking (standing enough) |
| Pulses | Normal | Reduced/absent |
| Skin | Normal | Pale, cool, trophic changes |
| Onset | Walking OR standing | Walking only |
| Bicycle test | Improves (leaning forward) | Worsens |
| Investigation | Findings |
|---|---|
| Plain X-ray (AP + Lateral) | Disc space narrowing, osteophytes ("lipping" of endplates), facet sclerosis, loss of lumbar lordosis, Schmorl's nodes, spondylolisthesis |
| Flexion-extension X-rays | Dynamic instability, segmental translational/angular movement |
| MRI (Gold Standard) | Dark disc (T2 signal loss), disc bulge/herniation, canal narrowing, nerve root compression, ligamentum flavum hypertrophy, facet effusions, Modic endplate changes; gadolinium for recurrent herniation post-surgery |
| CT scan | Superior bony detail; osteophytes, facet arthropathy; used when MRI contraindicated |
| CT Myelography | Gold standard for post-operative cases; defines neural compression with bony detail |
| EMG / Nerve Conduction Studies | Identifies affected nerve roots; differentiates radiculopathy from peripheral neuropathy |
| Discography | Controversial; provocation test to identify concordant pain generator; falling out of favour |
| Upright / standing MRI | Detects dynamic stenosis not apparent on supine imaging |
| Ankle-Brachial Index (ABI) | Rules out vascular claudication |
| Schober's test | Measures lumbar flexion |
| SLR / Crossed SLR | For disc herniation with radiculopathy |
| Bladder scan / urodynamics | If cauda equina suspected |
| Complication | Detail |
|---|---|
| Cauda equina syndrome | Acute large central disc herniation → saddle anaesthesia, urinary retention, bilateral weakness; surgical emergency - permanent incontinence and paraplegia if delayed |
| Permanent neurological deficit | Untreated radiculopathy → motor weakness, foot drop, sensory loss |
| Spondylolisthesis | Facet incompetence + disc collapse → vertebral slip (especially degenerative at L4-L5) |
| Progressive spinal deformity | Degenerative scoliosis or kyphosis |
| Chronic pain syndrome | Persistent low back pain with significant impact on quality of life and work |
| Failed back surgery syndrome | Post-operative persistent pain; recurrent disc herniation, adjacent segment disease, epidural fibrosis |
| Adjacent segment disease | Accelerated degeneration above/below a fusion |
| Osteoporotic fracture | Underlying osteoporosis + spondylosis combination common in elderly |
| Psychological complications | Depression, anxiety, sleep disturbance from chronic pain |
| Falls | Leg weakness, gait instability, and claudication increase fall risk in elderly |
| Deep Vein Thrombosis (post-operative) | Risk after spinal surgery with prolonged immobility |
Systemic lupus erythematosus
"lupus erythematosus"[MeSH Terms] AND diagnosis
| Factor | Detail |
|---|---|
| Genetic | HLA-DR2, HLA-DR3 associations; complement deficiencies (C1q, C2, C4 - especially C4A null allele); TREX1 mutations; IRF5, STAT4, BLK, PTPN22 gene variants |
| Hormonal | Oestrogen promotes B-cell hyperactivity; explains female predominance (F:M = 9:1); flares in pregnancy and with OCP use |
| UV light (sunlight) | Induces apoptosis → release of nuclear antigens → triggers flares and cutaneous manifestations |
| Infections | EBV (molecular mimicry with Sm antigen); other viral triggers |
| Drugs | Hydralazine, procainamide, isoniazid, minocycline, anti-convulsants, sulfonamides, penicillin, TNF inhibitors → drug-induced lupus (anti-histone antibodies) |
| Impaired apoptotic clearance | Deficient clearance of apoptotic debris → persistent nuclear antigen exposure → autoantibody formation |
| Type I Interferon pathway | Constitutive IFN-alpha overactivation drives autoimmunity |
| Ethnicity | More severe in African-Americans, Afro-Caribbeans, Asians, Hispanic populations |
| Type | Description |
|---|---|
| Systemic SLE | Full multiorgan involvement; meets ACR/SLICC/EULAR criteria |
| Cutaneous-only SLE | Discoid LE (DLE), subacute cutaneous LE (SCLE), acute cutaneous LE |
| Drug-induced Lupus | Triggered by specific medications; anti-histone antibodies; resolves on stopping drug |
| Neonatal Lupus | Transplacental anti-Ro/SS-A → congenital heart block, rash in neonate |
| Childhood/Juvenile SLE | Onset 3-15 years; girls > boys 4:1; often more severe than adult onset |
| Lupus with Antiphospholipid Syndrome | SLE + thrombosis + pregnancy morbidity + antiphospholipid antibodies |
| Overlap Syndrome | SLE features overlapping with other CTDs (RA, Sjögren's, systemic sclerosis, myositis) in ~25% |
| Factor | Detail |
|---|---|
| Sex | Female >90% of cases (F:M ~9:1) |
| Age | Reproductive age (15-45 years); peak onset 20-40 years |
| Genetics | HLA-DR2/DR3; complement deficiencies; positive family history |
| Ethnicity | African-American, Asian, Hispanic women at highest risk and severity |
| Hormonal | Oestrogen-containing OCP, pregnancy, postmenopausal HRT |
| UV exposure | Triggers and worsens disease |
| Drugs | See drug-induced lupus list above |
| Smoking | Associated with increased risk and disease activity |
| EBV infection | Molecular mimicry |
| Vitamin D deficiency | Associated with higher disease activity |
GENETIC SUSCEPTIBILITY (HLA-DR2/DR3, complement deficiency)
+ ENVIRONMENTAL TRIGGERS (UV, infections, drugs)
+ HORMONAL FACTORS (oestrogen)
│
▼
┌──────────────────────────────────┐
│ Increased Apoptosis / Impaired │
│ Clearance of Apoptotic Debris │
│ → Release of nuclear antigens │
│ (dsDNA, histones, Sm, Ro, La) │
└──────────────┬───────────────────┘
│
▼
┌──────────────────────────────────┐
│ Dendritic Cells Activated │
│ → TYPE I INTERFERON (IFN-α/β) │
│ overproduction ("IFN signature")│
└──────────────┬───────────────────┘
│
▼
┌──────────────────────────────────┐
│ B-cell Hyperactivation │
│ + Defective T-regulatory cells │
│ + Autoreactive T helper cells │
└──────────────┬───────────────────┘
│
▼
┌──────────────────────────────────┐
│ AUTOANTIBODY PRODUCTION │
│ • Anti-dsDNA (specific for SLE) │
│ • Anti-Sm (specific for SLE) │
│ • Anti-Ro/SS-A, Anti-La/SS-B │
│ • Anti-histone (drug-induced) │
│ • Antiphospholipid antibodies │
│ • Anti-C1q │
└──────────────┬───────────────────┘
│
▼
┌──────────────────────────────────┐
│ IMMUNE COMPLEX FORMATION │
│ (Ag-Ab complexes) │
│ → Deposited in tissues: │
│ kidneys, skin, joints, vessels│
└──────────────┬───────────────────┘
│
▼
┌──────────────────────────────────┐
│ COMPLEMENT ACTIVATION │
│ (C3a, C5a - anaphylatoxins) │
│ → Neutrophil/macrophage recruit.│
│ → Inflammatory cytokines (IL-1, │
│ IL-6, TNF-α) │
└──────────────┬───────────────────┘
│
▼
┌──────────────────────────────────┐
│ TISSUE INJURY │
│ • Glomerulonephritis (wire-loop)│
│ • Vasculitis │
│ • Serositis │
│ • Haematological cytopenias │
│ • CNS injury │
└──────────────────────────────────┘
| Test | Finding / Significance |
|---|---|
| ANA (antinuclear antibody) | Positive in >95%; sensitive but not specific; mandatory entry criterion (EULAR/ACR 2019) |
| Anti-dsDNA | Specific for SLE; titres correlate with disease activity (especially nephritis); used for monitoring |
| Anti-Sm | Highly specific for SLE (but only ~25-30% sensitive) |
| Anti-Ro/SS-A | Associated with photosensitivity, SCLE, neonatal lupus, Sjögren's overlap |
| Anti-La/SS-B | Usually with anti-Ro; neonatal lupus |
| Anti-histone | Drug-induced lupus |
| Antiphospholipid antibodies (anticardiolipin IgG/IgM, anti-β2GPI, lupus anticoagulant) | Thrombosis, recurrent miscarriage, false-positive VDRL/RPR |
| Complement (C3, C4, CH50) | Low in active disease (consumed by immune complex activation); rise with remission |
| Anti-C1q | Highly specific for lupus nephritis |
| FBC | Haemolytic anaemia, leukopenia, lymphopenia, thrombocytopenia |
| Direct Coombs test | Positive in haemolytic anaemia |
| ESR | Elevated in active disease (useful for monitoring) |
| CRP | Often normal in SLE; rises with serositis or bacterial infection - useful to distinguish flare from infection |
| Urinalysis + microscopy | Proteinuria, haematuria, RBC casts, granular casts |
| 24-hour urine protein / Spot PCR | Quantify proteinuria |
| Renal biopsy | Gold standard for lupus nephritis classification (ISN/RPS Classes I-VI); guides treatment |
| Skin biopsy (lupus band test) | IgG/IgM/C3 granular deposits at dermoepidermal junction (BMZ) on DIF |
| VDRL/RPR | False-positive (due to APL antibodies) |
| CT/MRI brain | Cerebral infarcts, white matter lesions in NPSLE |
| Echocardiography | Libman-Sacks vegetations, pericardial effusion, PAH |
| HRCT chest | ILD, pleural effusions |
| Renal function (eGFR, creatinine) | Monitor nephritis |
| Complication | Detail |
|---|---|
| Lupus nephritis → ESRD | Class III/IV worst prognosis; 10-year survival ~90% with treatment; ESRD in 10-20% |
| Cardiovascular disease | Accelerated atherosclerosis; MI risk 50x in young women with SLE; major cause of late mortality |
| Antiphospholipid syndrome | Recurrent DVT, PE, stroke, arterial thrombosis; recurrent miscarriages; catastrophic APS (multi-organ failure) |
| Infections | Leading cause of early mortality; from immune dysregulation + immunosuppressive therapy; common organisms: pneumococcus, salmonella, herpes viruses |
| NPSLE | Seizures, stroke, psychosis, transverse myelitis; significant morbidity |
| Avascular necrosis | Femoral head; from both disease vasculitis and corticosteroid therapy |
| Osteoporosis | From corticosteroid use + reduced physical activity |
| Drug toxicity | Steroid side effects; hydroxychloroquine retinopathy; cyclophosphamide-induced infertility/bladder toxicity |
| Malignancy | NHL risk elevated; also skin and cervical cancer |
| Neonatal lupus | Congenital complete heart block; transient rash; from anti-Ro antibody transfer |
| Pregnancy complications | Miscarriage, pre-eclampsia, IUGR, preterm delivery; especially with active nephritis and APL antibodies |
| Pulmonary hypertension | Serious; associated with anti-RNP antibodies and Raynaud's phenomenon |
| Shrinking lung syndrome | Progressive dyspnoea from diaphragmatic dysfunction |
| Psychological morbidity | Depression, anxiety from chronic disease + CNS involvement |
Elisa test